作者
Seth C Inzaule, Raph L Hamers, Marc Noguera-Julian, Maria Casadellà, Mariona Parera, Cissy Kityo, Kim Steegen, Denise Naniche, Bonaventura Clotet, Tobias F Rinke de Wit, Roger Paredes, Akin Osibogun, Carole L Wallis, Cathy Nalubwama, Esrom Letsoalo, Fred Senono, Hameed Adelabu, Hanipha Kakooza, Harriet Namata, Ian Sanne, Immaculate Nankya, Jack Menke, Joep MA Lange, Kim CE Sigaloff, Kishor Mandaliya, Margaret Hardman, Margaret Siwale, Marleen de Jager, Marian Dolan, Mariette E Botes, Martin O'Mello, Maureen Wellington, Miiro Mutebi, Miriam Nakitto, Moheb Labib, Nadine Pakker, Pascale Ondoa, Peter Mugyenyi, Prudence Ive, Ritah Nakanjako, Rob Schuurman, Ruedi Lüthy, Sheila N Balinda, Sulaimon Akanmu, T Sonia Boender, Titilope A Adeyemo, Tope Rodoye, Wendy S Stevens, Winnie Namala
发表日期
2018/11/1
期刊
The Lancet HIV
卷号
5
期号
11
页码范围
e638-e646
出版商
Elsevier
简介
Background
Implementation of ultrasensitive HIV drug resistance tests for routine clinical use is hampered by uncertainty about the clinical relevance of drug-resistant minority variants. We assessed different detection thresholds for pretreatment drug resistance to predict an increased risk of virological failure.
Methods
We did a case-control study nested within a prospective multicountry cohort. Our study included patients from 12 clinical sites in Kenya, Nigeria, South Africa, Uganda, and Zambia. We defined cases as patients with virological failure (ie, those who had either viral load ≥400 copies per mL at 12 months or had switched to second-line antiretroviral therapy [ART] as a result of virological failure before 12 months) and controls as those with viral suppression (viral load <400 copies per mL at 12 months) on first-line non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. We assessed …
学术搜索中的文章
SC Inzaule, RL Hamers, M Noguera-Julian… - The Lancet HIV, 2018